Calciumgaben bei Osteoporose – mehr Schaden als Nutzen?

Autor: Andreas Hahn, Alexander Ströhle

 

  1. Bhattacharya RK. Does widespread calcium supplementation pose cardiovascular risk? No: concerns are unwarranted. Am Fam Physician. 2013 Feb 1;87(3):Online.
  2. Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, Gamble GD, Grey A, Reid IR. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008 Feb 2;336(7638):262-6.
  3. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010 Jul 29;341:c3691.
  4. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011 Apr 19;342:d2040.
  5. Bonjour JP, Kraenzlin M, Levasseur R, Warren M, Whiting S. Dairy in adulthood: from foods to nutrient interactions on bone and skeletal muscle health. J Am Coll Nutr. 2013;32(4):251-63
  6. Challoumas D, Cobbold C, Dimitrakakis G. Effects of calcium intake on the cardiovascular system in postmenopausal women. Atherosclerosis. 2013 Nov;231(1):1-7.
  7. Deutsche Gesellschaft für Ernährung (DGE), Österreichische Gesellschaft für Ernährung (ÖGE), Schweizerische Gesellschaft für Ernährungsforschung (SGE), Schweizerische Vereinigung für Ernährung (SVE). Referenzwerte für die Nährstoffzufuhr. Calcium. Neuer Umschau Buchverlag, Neustadt a. d. Weinstraße, 1. Auflage, 5., korrigierter Nachdruck, 2013, S. 189-217
  8. DVO-Leitlinie 2014 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. www.dv-osteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20Kurzfassung%20und%20Langfassung%2018.%2009.%202014.pdf; zuletzt abgerufen am 27.02.2015
  9. EFSA; Scientific Committee on Food Scientific Panel on Dietetic Products, Nutrition and Allergies. Tolerable upper intake levels for vitamins and minerals, 2006. Online verfügbar unter www.efsa.europa.eu/de/ndatopics/docs/ndatolerableuil.pdf
  10. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the Tolerable Upper Intake Level of calcium. EFSA Journal 2012;10(7):2814.
  11. FAO/WHO (Food and Agricultural Organisation of the UN/World Health Organisation) Expert Consultation. Application of risk analysis to food standards issues. Recommendations to the Codex Alimentarius Commission (ALINORM 95/9, Appendix 5) 1995.
  12. FNB (Food and Nutrition Board, Institute of Medicine, National Academy of Sciences). Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. National Academy Press, Washington DC 1997.
  13. FNB (Food and Nutrition Board, Institute of Medicine, National Academy of Sciences). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academy Press, Washington DC 1998.
  14. FNB (Food and Nutrition Board, Institute of Medicine, National Academy of Sciences). Dietary Reference Intakes for Vitamin C, Vitamin E, Carotenoids and Selenium. National Academy Press, Washington DC 2000.
  15. Hahn A, Ströhle A. Sicherheit von Vitaminen und Mineralstoffen, Schweizer Zeitschrift für Ernährungsmedizin 2014 14;(4):22-28.
  16. Heaney RP, Kopecky S, Maki KC, Hathcock J, Mackay D, Wallace TC. A review of calcium supplements and cardiovascular disease risk. Adv Nutr. 2012 Nov 1;3(6):763-71.
  17. Institute of Medicine (IOM) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. Online verfügbar unter: www.ncbi.nlm.nih.gov/books/NBK56070/.
  18. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23-57.
  19. Lewis JR, Zhu K, Prince RL. Adverse events from calcium supplementation: relationship to errors in myocardial infarction selfreporting in randomized controlled trials of calcium supplementation. J Bone Miner Res. 2012;27:719–22.
  20. Lewis JR, Radavelli-Bagatini S, Rejnmark L, Chen JS, Simpson JM, Lappe JM, Mosekilde L, Prentice RL, Prince RL. The Effects of Calcium Supplementation on Verified Coronary Heart Disease Hospitalization and Death in Postmenopausal Women: A Collaborative Meta-Analysis of Randomized Controlled Trials. J Bone Miner Res. 2014 Jul 10. doi: 10.1002/jbmr.2311. [Epub ahead of print] PubMed PMID: 25042841.
  21. Mason P. One is okay, more is better? Pharmacological aspects and safe limits of nutritional supplements. Proc Nutr Soc. 2007 Nov; 66 (4): 493-507.
  22. McDaniel MH, Williams SE. Calcium primer: current controversies and common clinical questions. J Clin Densitom. 2013 Oct-Dec;16(4):389-93.
  23. Nordin BE, Lewis JR, Daly RM, Horowitz J, Metcalfe A, Lange K, Prince RL. The calcium scare--what would Austin Bradford Hill have thought? Osteoporos Int 2011;22:3073-7.
  24. Ulbig, R. F. Hertel, G.-F. Böl (Hrsg.): Evaluierung der Kommunikation über die Unterschiede zwischen „risk“ und „hazard“, Abschlussbericht, Bundesinstitut für Risikobewertung 2009. www.bfr.bund.de/cm/350/evaluierung_der_kommunikation_ueber_die_unterschiede_zwischen_risk_und_hazard.pdf am 09.09.2014)
  25. Paik JM, Curhan GC, Sun Q, Rexrode KM, Manson JE, Rimm EB, Taylor EN. Calcium supplement intake and risk of cardiovascular disease in women. Osteoporos Int 2014;25:2047-56.
  26. Prentice RL, Pettinger MB, Jackson RD, et al. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int 2013;24:567-80.
  27. Rojas-Fernandez CH, Maclaughlin EJ, Dore NL, Ebsary S. Assessing the potential adverse consequences of supplemental calcium on cardiovascular outcomes: should we change our approach to bone health? Ann Pharmacother. 2012 May;46(5):696-702.
  28. Spence LA, Weaver CM. Calcium intake, vascular calcification, and vascular disease. Nutr Rev. 2013 Jan;71(1):15-22.
  29. Ströhle A, Hahn A. Nährstoffsupplemente - Möglichkeiten und Grenzen. Teil 5: Supplemente in der Primärprävention - Methodologische Aspekte, Med Monatsschrift Pharm 2014a; 37 (1):13-26.
  30. Ströhle A, Hahn A. Nährstoffsupplemente - Möglichkeiten und Grenzen. Teil 6: Sicherheit und mögliche Risiken, Med Monatsschr Pharm. 2014b; 37 (7): 249-256.
  31. Ströhle A, Hadji P, Hahn A. Calcium and bone health - Goodbye, calcium supplements?, Climacteric. 2015 Feb 18:1-18. [Epub ahead of print]
  32. Wallace RB, Wactawski-Wende J, O'Sullivan MJ, Larson JC, Cochrane B, Gass M, Masaki K. Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomizedclinical trial of calcium and vitamin D supplements. Am J Clin Nutr. 2011 Jul;94(1):270-7.
  33. Wang L, Manson JE, Sesso HD. Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials. Am J Cardiovasc Drugs. 2012 Apr 1;12(2):105-16.
  34. Weaver CM. Calcium is not only safe but important for health. In: Burckhardt P, Dawson-Hughes B, Weaver C. Nutritional Influences on Bone Health. Springer, London 2013:359-363.
  35. Weaver CM. Calcium supplementation: is protecting against osteoporosis counter to protecting against cardiovascular disease? Curr Osteoporos Rep. 2014 Jun;12(2):211-8.
  36. Willers J, Heinemann M, Bitterlich N, Hahn A. Intake of minerals from food supplements in a german population – a nationwide survey. Food and Nutrition Sciences 2015a, 6:205-215.
  37. Willers J, Heinemann M, Bitterlich N, Hahn A. Vitamin intake from food supplements in a German cohort - is there a risk of excessive intake?, Int. J. Vitam. Nutr. Res.2015b (in press).

 

 

Differenzierte Evidenz für Wirksamkeit und Sicherheit von Traubensilberkerze zur Behandlung klimakterischer Beschwerden

Autor: André-Michael Beer

 

  1. EMA European Medicine Agency. Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome. EMA/HMPC/600717/2007 Corr., first published 20/01/2011, last updated 26/04/2011.
  2. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012;Sep 12;9:CD007244. doi: 10.1002/14651858.CD007244.pub2.
  3. Beer A-M, Osmers R, Schnitker J, Bai W, Mueck AO, Meden H. Efficacy of black cohosh (Cimicifuga racemosa) medicines for treatment of menopausal symptoms – comments on major statements of the Cochrane Collaboration report 2012 "black cohosh (Cimicifuga spp.) for menopausal symptoms /review)". Gynecol Endocrinol 2013;29(12):1022-5.
  4. Beer A-M, Neff A. Differentiated evaluation of extract-specific evidence on Cimicifuga racemosa's efficacy and safety for climacteric complaints. Evid based Complement Alternat med 2013; Article ID 860602, dx.doi.org/10.1155/2013/860602.
  5. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin H-H. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005;105:1074-83.
  6. Bai W, Henneicke-von Zepelin HH, Wang S, Zheng S, Liu J, Zhang Z, Geng L, Hu L, Jiao C, Liske E. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007;58:31-41.
  7. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005;20(1):30-5.
  8. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247-55.
  9. Liske E, Hänggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P. Rahlfs VW. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002;11(2):163-74.
  10. Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment - results of a large-scale, controlled, observational study. Maturitas 2007;57:405-14.
  11. Schmidt M, Polasek W, Käufeler R. Wirksamkeit und Sicherheit von Traubensilberkerze (Cimicifuga racemosa, Cimifemin®) bei Menopausebeschwerden: Therapiebeobachtung unter Praxisbedingungen. J Menopause 2005;12(1):30-4.
  12. Vermes G, Banhidy F, Acs N. The Effects of Remifemin® on Subjective Symptoms of Menopause. Adv Ther 2005;22(2):148-54.
  13. Julia Molla MD, Garcia-Sanchez Y, Sarrio AR, Perez-Lopez FR. Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women. Gynecol Endocrinol 2009;25(1):21-6.
  14. Wuttke W, Seidlová-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003;44(Suppl.l):67-77.
  15. Wuttke W, Raus K, Gorkow C. Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study. Maturitas 2006;55:83-91.
  16. Raus K, Brucker C, Gorkow C, Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause 2006;13(4):678-91.
  17. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer Ch, Birkhäuser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005;51:397-404.
  18. Oktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscu E, Zeyneloglu HB. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther 2007;24(2):448-61.
  19. Kaiser WD, Martin R, Schellenberg R, Schrader E, Saller R. Cimicifuga-racemosa-Extrakt Ze 450 bei Wechseljahrbeschwerden. Ars Medici 2008;17:771-4.
  20. Chung DJ, Kim HY, Park KH, Jeong KA, Lee SK, Lee YI, Hur SE, Cho MS, Lee BS, Bai SW, Kim CM, Cho SH, Hwang JY, Park JH. Black cohosh and St. John's Wort (GYNO-Plus®) for climacteric symptoms. Yonsei Med J 2007;48(2):289-94.
  21. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145(12):869-79.
  22. Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, Hedayat S, Nikolic D, Krause EC, Piersen CE, Bolton JL, Pauli GF, Farnsworth NR. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16(6):1156-66.
  23. Ruhlen RL, Haubner J, Tracy JK, Zhu W, Ehya H, Lamberson WR, Rottinghaus GE, Sauter ER. Black cohosh does not exert an estrogenic effect on the breast. Nutr Cancer 2007;59(2):269-77.
  24. Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomised controlled clinical trials for isopropanolic black cohosh extract. Menopause 2011;18(4):366-75.
  25. Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D, Lo KM, Moore A, Rosenman PJ, Kaufman EL, Neugut AI, Grann VR. Randomized Trial of Black Cohosh for the Treatment of Hot Flashes Among Women With a History of Breast Cancer. J Clin Oncol 2001;19(10):2739-45.
  26. Garcia-Perez MA, Pineda B, Hermenegildo C, Tarín JJ, Cano A. Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line. Fertil Steril 2009;91(4,Suppl):1347-50.
  27. Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL, Hagenmaier A, Zhang H, Lambert GH, Reeser KA, Wisbey JA. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest 2004;22(4):515-21.
  28. Lindén-Hirschberg A, Edlund M, Svane G, Azavedo E, Skoog L, von Schoultz B. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause 2007;14(1):89-96.
  29. Reame NE, Lukacs JL, Padmanabhan V, Eyvazzadeh AD, Smith YR, Zubieta JK. Black cohosh has central opiod activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008;15(5):832-40.
  30. Rostock M, Fischer J, Mumm A, Stammwitz U, Saller R, Bartsch HH. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecol Endocrinol 2011;27(10):844-8.
  31. Lundström E, Hirschberg AL, Söderqvist G. Digitized assessment of mammographic breast density. Effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. Maturitas 2011;70(4):361-4.
  32. Rebbeck TR, Troxel AB, Norman S, Bunin GR, DeMichele A, Baumgarten M, Berlin M, Schinnar R, Strom BL. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer 2007;120:1523-8.
  33. Obi N, Chang-Claude J, Berger J, Braendle W, Slanger T, Schmidt M, Steindorf K, Ahrens W, Flesch-Janys D. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiol Biomarkers Prev 2009;18(8):2207-13.
  34. Henneicke-von Zepelin HH, Meden H, Kostev K, Schröder-Bernhardi D, Stammwitz U, Becher H. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Intern J Clin Pharmacol Ther 2007;45(3):143-54.
  35. Hernández-Munoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003;44 (Suppl I):59-65.
  36. Nasr A, Nafeh H. Influence of black cohosh (Cimicifuga racemosa) use by postmenopausal women on total hepatic perfusion and liver functions. Fertil Steril 2009;92(5):1780-2.
  37. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15(1):51-8.
  38. Brasky TM, Lampe JW, Potter JD, Patterson RE, White E. Speciality Supplements and Breast Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiol Biomarkers Prev 2010;19(7):1696-708.
  39. Firenzuoli F, Gori L, Roberti di Sarsina P. Black Cohosh Hepatic Safety: Follow-Up of 107 Patients Consuming a Special Cimicifuga racemosa rhizome Herbal Extract and Review of Literature. Evid Based Complement Alternat Med 2011;821392. doi:10.1093/ecam/nen009.

Phytopharmaka bei Wechseljahrsbeschwerden

Autor: André-Michael Beer

 

  1. Beer AM, Adler M (eds). Leitfaden für Naturheilverfahren für die ärztliche Praxis. München: Elsevier, 2011, 1. Aufl. 
  2. Schilcher H; Loew D (2013).  Phytopharmaka als Alternative zu Synthetika. MMW-Fortschr Med,Originalien IV 155 (4): 97-99
  3. EMA European Medicine Agency. Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome. EMA/HMPC/600717/2007 Corr., first published 20/01/2011, last updated 26/04/2011.
  4. Beer A-M, Neff A. Differentiated evaluation of extract-specific evidence on Cimicifuga racemosa's efficacy and safety for climacteric complaints. Evid based Complement Alternat med 2013; Article ID 860602, dx.doi.org/10.1155/2013/860602.
  5. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms.Cochrane Database Syst Rev 2012;Sep 12;9:CD007244. doi: 10.1002/14651858.CD007244.pub2.
  6. Beer A-M, Osmers R, Schnitker J, Bai W, Mueck AO, Meden H. Efficacy of black cohosh (Cimicifuga racemosa) medicines for treatment of menopausal symptoms – comments on major statements of the Cochrane Collaboration report 2012 "black cohosh (Cimicifuga spp.) for menopausal symptoms /review)". Gynecol Endocrinol 2013;29(12):1022-5. 
  7. Beer AM. Cimicifuga racemosa bei klimaterischen Beschwerden. Aktuelle Daten bestätigen Wirksamkeit und Sicherheit. Z Phytotherapie 2015;36: 10-17
  8. Stute P, Pickartz S. Zusatznutzen eines isopropanolischen Cimicifuga-racemosa-Extraktes (iCR). Positive Beeinflussung von Knochenstoffwechsel und –qualität. Z Phytotherapie 2015; 36: 18–22 
  9. Seidlová-Wuttke D. Schützt Cimicifuga-Spezialextrakt vor Osterporose? NaturaMed 2009 1 (24)
  10. Liske E, Henneicke-von Zepelin HH, Pickartz S, Meden H. Wirkung des isopropanolischen Cimicifuga-racemosa-Extrakts iCR auf Uterusmyome bei Frauen mit klimakterischen Beschwerden. Z Phytotherapie 2015; 36: 23–26
  11. Xi S, Liske E, Wang S et al. Effect of isopropanolic Cimicifuga racemosa extract on uterine fibroids in comparison with Tibolone among patients of a recent randomized, double blind, parallel-controlled study in Chinese women with menopausal symptoms. Evid Based Complement Altern Med. 2014;2014:717686
  12. Beer AM (2014). Traubensilberkerze und Rapontikrhabarber bei klimakterischen Beschwerden. Evidenz spricht für die Phytotherapie. MMW-Fortschr Med, 156 (8): 40-41
  13. Beer AM. Vitex agnus-castus: Evidenzbasierte Therapie bei zyklusabhängigen Beschwerden. Z Phytotherapie 2015; 36: 4–9
  14. Kommission E. Monographie Agni casti fructus (Keuschlammfrüchte). BAnz 1992; 226
  15. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC) Assessment report on Vitex agnus-castus L., fructus, 2011.25 November 2010 EMA/HMPC/144003/2009
  16. Deutsche Pharmazeutische Gesellschaft e.V.: Gute Substitutionspraxis. Leitlinie, Stand: 24.2.2014

Behandlung akuter Vulvovaginalmykosen mit Clotrimazol

Autoren: Hans-Jürgen Tietz, Ingo Stock, Morbert Becker

 

  1. Hamad M, Kazandji N, Awadallah S, Allam H. Prevalence and epidemiological characteristics of vaginal candidiasis in the UAE. Mycoses 2014;57:184–90.
  2. Matter-Walstra K. Chronisch-vaginale Pilzinfekte – Untersuchungen zur Lebensqualität betroffener Frauen. Schweiz Zschr Ganzheits Medizin 2000;205–11.
  3. Mendling W. Vaginitis, Zervizitis und Salpingitis. Springer Medizin Verlag, 2. Auflage. Heidelberg 2006.  
  4. Petersen-Braun M, Gessner U. Was wir von Feldstudien lernen können. Pharm Zeitung 2000; 145:4412–9.
  5. Ritter W. Canesten – lange Wirkstoffverfügbarkeit durch verbesserte Galenik. In: Alstaeder DmR (Hrsg.). Vaginalmykosen: Therapie von heute im Trend von morgen, Canesten. Bayer AG, Leverkusen 1987;26–9.
  6. Romeo O, Tietz H-J, Criseo G. Candida africana: is it a fungal pathogen? Curr Fungal Infect Rep 2013;7:192–7.
  7. Stock I. Pilzerkrankungen der Vulva und Vagina durch Candida-Arten. Erreger, Krankheitsbilder und Behandlungsoptionen. Med Monatsschr Pharm 2010;33:324–33.
  8. Tietz H-J. Behandlung akuter Vaginalmykosen mit Clotrimazol. Vergleich der topischen Ein- und Dreitagekombinationstherapie. gyne 2011;11:12–5.
  9. Tietz H-J. Mykosen in der Gynäkologie. Frauenarzt 2014;55:28–33.
  10. Tietz H-J. Therapieproblem chronisch rezidivierende Vaginalmykose. Ther Umschau 2002; 59:481–4. 
  11. Tietz H-J, Becker N. Akute Vaginalmykose. Vergleichende Untersuchung der 1- und 3-Tage-Therapie mit Clotrimazol. Pharm Zeitung 2009;154:1437–42.

Seniorin mit Brustkrebs will keine OP – was tun?

Autor: J.M. Wenderlein

 

  1. Hind D et al:Surgery with or without tamoxifen versus tamoxfen alone for older women with operable breast cancer (70 years plus) Cochrane review.Br J Cancer 2007 Apr10,96(7) 1025–9.Epub2007Feb 6
  2. De Glas NAet al:Impact of ommission of surgery on survival of older patients with breast cancer.Br JSurg 2014 online 4. August;doi:10.1002.9616
  3. Brown WJ et al. Comparing population attributable risks for heart disease across the adult lifespan in women. BJSM, online 8. Mai 2014; doi: 10.1136/bjsports-2013-093090  
  4. Faletti MG et al. Brain and Cognition 2005; 59: 60–70
  5. Stewart A et al. Clin Neuropsychol 2006; 20: 76–89
  6. Fauser F., M. Wenderlein :Antihormonelle Therapie bei Brustkrebs: Studien sprechen für Vorteile von Tamoxifen hinsichtlich des Risikos für ischämische Insulte. Frauenarzt 54(2013)10:990–993
  7. Davies C. et al: (for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.Lancet. 2012 Dec 4. pii: S0140-6736(12)61963-1. DOI: 10.1016/S0140-6736(12)61963-1.
  8. Biersack et al:Spätfolgen onkologischer Therapie.Der Internist 2013,54:1221–1232.DOI 10.1007/s00108-013-3355-z.
  9. Planaet JC et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Society of Echocardiography 2014:27:911–39
  10. Scherling CS, Sensors (Basel) 2013; 13 (3): 3169–3203
  11. Hutchinson AD et al. Cancer Treat Rev 2012; 38: 926–34
  12. Erickson KI, Neurobiol of Aging 2014; 35(2): 20–281.
  13. Karle J et al:Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Res Treat(2013)139:553–560